Pharma Surge
Pharma Surge
Intelligence Layer
🇺🇸·Apr 28Research

The CADENCE Trial: Activin Type II Receptor Ligand Trapping With Sotatercept as First Prospective Proof-of-Concept for the Adipokine Hypothesis of Heart Failure With Preserved Ejection Fraction

Publisher

J
Journal of Cardiac Failure

USA

This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.

Read original

At a glance

Publisher
Journal of Cardiac Failure
Region
USA
Scope
Research
Published
April 28, 2026

In-platform summary, original article off-platform

This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.

Source route

Continue on onlinejcf.com

Leave the platform to read the original full article on the publisher site.

Source: Journal of Cardiac Failure

Scope: Research

Open original article
The CADENCE Trial: Activin Type II Receptor Ligand Trapping With Sotatercept as First Prospective Proof-of-Concept for the Adipokine Hypothesis of Heart Failure With Preserved Ejection Fraction | Pharma Surge